Can PYC Therapeutics (ASX:PYC) Justify Its Valuation On Full Year Earnings?
What PYC Therapeutics’ Latest Earnings Mean For Investors
PYC Therapeutics (ASX:PYC) drew investor attention after reporting full year earnings to 30 June 2026, with revenue of A$39.68 million and a net loss of A$43.34 million from continuing operations.
The earnings release on 28 August appears to sit alongside strong recent momentum in PYC Therapeutics. The share price is A$2.57 after a 30 day share price return of 28.82% and a 90 day share price return of 108.10%. The 1 year total shareholder return of 107.22% and 3 year total shareholder return of 361.66% indicate this recent strength has built over a longer period.
See how PYC Therapeutics compares with other high momentum biotech stocks by reviewing our hand picked list of 13 high quality undiscovered gems in similar high growth areas.
Bulls point to PYC Therapeutics’ strong recent share price gains and improving earnings metrics. Bears focus on the ongoing losses and clinical risks. Which side does the current valuation favour as you weigh the next move?
Preferred Price-to-Book Multiple of 3.6x on PYC Therapeutics: Is It Justified?
PYC Therapeutics trades on a P/B of 3.6x, which sits below both its peer group at 6.3x and the broader Australian Biotechs industry at 3.9x. That gap suggests the market is assigning a lower valuation to PYC Therapeutics’ equity base compared with similar companies, despite the strong recent share price performance.
The P/B multiple compares the company’s market value to its book value of equity. For a clinical stage biotech like PYC Therapeutics that is currently loss making, this can be a useful yardstick because earnings based measures are less meaningful. Investors are effectively weighing the market value of PYC Therapeutics’ pipeline, intellectual property and balance sheet against the accounting value recorded today.
Relative to peers on 6.3x, PYC Therapeutics’ 3.6x P/B implies the market is applying a lower premium to its assets than to those of comparable Australian biotech stocks. This lower multiple may reflect the company’s ongoing losses, the expectation of no revenue next year and the fact that it is not forecast to reach profitability over the next three years. Compared with the broader Australian Biotechs industry on 3.9x, the discount is smaller but still present, which keeps PYC Therapeutics positioned toward the lower end of the sector’s valuation range on this metric.
To see how this P/B value stacks up against a more detailed fair value framework and what that might imply for PYC Therapeutics, review the full valuation breakdown in the See what the numbers say about this price — find out in our valuation breakdown.
Result: Price-to-book of 3.6x (ABOUT RIGHT)
However, PYC Therapeutics still carries material clinical trial and ongoing loss risks that could quickly challenge sentiment if key programs disappoint or if funding conditions tighten.
Find out about the key risks to this PYC Therapeutics narrative.
Next Steps
Does this earnings picture leave you optimistic or cautious about PYC Therapeutics? Take a moment to review the key numbers, consider your own risk tolerance, and then weigh the 2 important warning signs.
Looking For More Investment Ideas Beyond PYC Therapeutics?
If you are weighing what to do next after reviewing PYC Therapeutics, do not stop here. Broader ideas can help you stress test your thinking.
- Scan for potential bargains by reviewing our hand picked 12 high quality undervalued stocks that combine solid fundamentals with a price the market may be overlooking.
- Prioritise resilience first and see which companies feature in our 14 resilient stocks with low risk scores so you are not caught off guard by hidden weak spots.
- Strengthen your core holdings with companies from our list of solid balance sheet and fundamentals (21 results) and keep your portfolio prepared for whatever comes next.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com